Spyre Therapeutics' SPY001 Shows Strong Phase 1 Results in IBD Treatment
Spyre's SPY001 shows long-lasting effects and good tolerance in Phase 1 IBD trial, moving to Phase 2.
.webp&w=1920&q=75&dpl=dpl_DvHKTkTrxtw9jHK6MpkEndZCmmr3){kind=logo}
Spyre Therapeutics has announced encouraging interim Phase 1 trial results for SPY001, its extended half-life monoclonal antibody targeting α4β7 for inflammatory bowel disease (IBD). The investigational drug demonstrated both excellent tolerance and sustained pharmacokinetic performance, showing a half-life of over 90 days, which could support extended maintenance dosing every three to six months. Positive pharmacodynamic data showed complete receptor engagement at all time points, underscoring SPY001's potential as a next-generation treatment. Spyre anticipates advancing SPY001 into a Phase 2 platform trial for ulcerative colitis in 2025, alongside additional investigational therapies, for improved IBD treatment outcomes.
The upcoming Phase 2 trial aims to assess SPY001 as both a standalone and a foundational therapy in combination regimens.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Curia New York reçoit une lettre d’avertissement de la FDA concernant des milliers d’injections chromatographiques non documentées
Ab Science révise les calendriers d'essais après trois inspections GCP
Discussion